Evidence map›Paper›PMID 31129638›Full record

ArticleBMJ case reports2019

Rapidly progressive global cerebral atrophy in the setting of anti-LGI1 encephalitis.

Anudeep Yelam, Elanagan Nagarajan, Pradeep C Bollu

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Anudeep Yelam *Department of Neurology, University of Missouri Health Care, Columbia, Missouri, USA.
Elanagan Nagarajan *Department of Neurology, Howard Hughes Medical Institute - University of Missouri Columbia School of Medicine, Columbia, Missouri, USA.ORCID http://orcid.org/0000-0003-0521-9485
Pradeep C BolluDepartment of Neurology, University of Missouri Health Care, Columbia, Missouri, USA.ORCID http://orcid.org/0000-0002-5364-4606
University of Missouri Health System · USHoward Hughes Medical Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 47-year-old man presented with complaints of breakthrough seizures, psychiatric and behavioural changes and catatonic features. MRI of the brain showed mild cerebral and right hippocampal atrophy, while the electroencephalogram showed intermittent right temporal slowing. With a presumed diagnosis of autoimmune encephalitis, he was treated with intravenous immunoglobulin (IVIG) and methylprednisolone, which significantly improved the symptoms. Serological testing later was positive for antileucine-rich glioma inactivated 1 antibody. Two months after the initial presentation, patient had a relapse of the symptoms without any further episodes of seizures. Repeat MRI of the brain showed a significant rapidly progressive diffuse cortical atrophy and hippocampal atrophy, more prominent on the right side along with hydrocephalus ex vacuo when compared with the initial MRI. He is currently on monthly IVIG therapy. At 4 months follow-up from the second imagining study, the patient had persistent MRI findings.

Indexed as

AtrophyBrainDementiaEncephalitisHumansIntracellular Signaling Peptides and ProteinsMagnetic Resonance ImagingMaleMiddle AgedSeizuresIntracellular Signaling Peptides and ProteinsLGI1 protein, humanepilepsy and seizureshydrocephalusimmunologyneuro geneticsneuroimaging

Identifiers

PMID31129638
PMCPMC6536266
OpenAlexW2945187401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.